ReviewAAPS PharmSciTech2025
Advances in 3D Printed Microneedles as a Prototype for Skin Targeted Therapeutics in Personalized Dermal Pharmaceuticals.
Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the evolving realm of skin delivery, the shortcomings of traditional drug delivery practices have encouraged the emergence of innovative therapeutics using next generation- 3D printed microneedles. Next-generation microneedles, fabricated using advanced 3D printing technology, offer a precise and targeted approach to overcome the challenges of poor skin penetration over traditional topical therapies. By creating micro-scale channels on the skin, 3D microneedles facilitate the efficient delivery of cosmeceuticals, addressing a spectrum of skin concerns such as atopic dermatitis, psoriasis, alopecia, skin tumors, diabetic wound, hyperpigmentation, wrinkles and acne scars. PubMed analysis reveals a significant rise in 3D printed microneedle publications from 10 in 2000 to over 350 in 2025, with more than 65 clinical trials registered between 2010 and 2025. The intersection of microneedle technology and dermatology presents a promising avenue for personalized treatment. We elucidated the latest advancements and future directions to guide researchers and clinicians toward the development of safe and effective drug delivery interventions in the ongoing battle against the severity of skin diseases. Furthermore, the prospects of 3D printed microneedles with ongoing advances in biomimetism indicate potential translation into reliable, and scalable pharmaceutical. Nevertheless, further research is warranted to optimize formulations, ensure biocompatibility, and unlock their full potential in revolutionizing the field.
Indexed as
Identifiers
41345791What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.